EUVIMEDEUVIMED entdecken
Crossref

PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway

Menghuai Ma, Fan Liu, Xiaomei Yin, Jianhong Yue, Yanhua Duan, Jiong Tang

General physiology and biophysics · 2026 · 45 (02) · 153-165

DOI: 10.4149/gpb_2025043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift General physiology and biophysics, 2026. Verfasst von Menghuai Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical Universit…. Hauptthemen laut MEDLINE: Atherosclerosis, PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized, Reactive Oxygen Species.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisPCSK9 InhibitorsAntibodies, Monoclonal, HumanizedReactive Oxygen SpeciesMAP Kinase Signaling SystemEndothelial CellsAnimalsHumansMiceProprotein Convertase 9MaleOxidative StressDisease ProgressionApoptosisHuman Umbilical Vein Endothelial CellsLipoproteins, LDLMice, Inbred C57BL

Substanzen

PCSK9 InhibitorsevolocumabAntibodies, Monoclonal, HumanizedReactive Oxygen SpeciesProprotein Convertase 9Lipoproteins, LDLoxidized low density lipoprotein

Autor:innen und Institutionen

  • Department of Cardiology, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.

Zitieren

APA

Ma, M., Liu, F., Yin, X., Yue, J., Duan, Y., & Tang, J. (2026). PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway. General physiology and biophysics, 45(02), 153-165. https://doi.org/10.4149/gpb_2025043

Vancouver

Ma M, Liu F, Yin X, Yue J, Duan Y, Tang J. PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway. General physiology and biophysics. 2026;45(02):153-165. doi:10.4149/gpb_2025043

BibTeX
@article{Ma2026,
  author = {Ma, Menghuai and Liu, Fan and Yin, Xiaomei and Yue, Jianhong and Duan, Yanhua and Tang, Jiong},
  title = {PCSK9 inhibitor Evolocumab alleviates atherosclerosis progression by suppressing endothelial cell injury via the ROS/MAPK pathway},
  journal = {General physiology and biophysics},
  year = {2026},
  volume = {45},
  number = {02},
  pages = {153--165},
  doi = {10.4149/gpb_2025043}
}
Kostenlos starten →